rituximab

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Conditions

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Trial Timeline

Apr 1, 1995 → —

NCT ID

NCT00168740

About rituximab

rituximab is a phase 3 stage product being developed by Biogen for Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00168740. Target conditions include Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00476515	Phase 1	Withdrawn	Mar 1, 2007	Sep 1, 2007	Kidney Insufficiency
NCT00584935	Phase 1/2	Completed	Jan 1, 2006	May 1, 2010	Ocular Cicatricial Pemphigoid
NCT00588822	Phase 2	Terminated	Jan 1, 2005	Feb 1, 2011	Precancerous Condition
NCT00090038	Approved	Completed	Oct 1, 2003	Nov 1, 2007	Non-Hodgkin's Lymphoma
NCT01713738	Phase 1/2	Completed	May 1, 2003	Dec 1, 2005	Idiopathic Thrombocytopenic Purpura (ITP)
NCT00031642	Phase 1/2	Completed	Jan 1, 2002	Mar 1, 2008	Lymphoma
NCT00168740	Phase 3	Completed	Apr 1, 1995	—	Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Competing Products

13 competing products in Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Rabeprazole Sodium	Eisai	Pre-clinical	23
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	52
Everolimus	Novartis	Phase 2	52
MEK162, MEK inhibitor; oral + Physician's choice chemotherapy	Pfizer	Phase 3	76
Fludarabine Phosphate (Fludara) + Rituximab	Sanofi	Phase 2	51
Tovorafenib	Ipsen	Phase 1	30
Tovorafenib	Day One Biopharmaceuticals	Phase 2	47
Tovorafenib + Chemotherapeutic Agent	Day One Biopharmaceuticals	Phase 3	72
DAY101	Day One Biopharmaceuticals	Phase 1	28
Tovorafenib	Day One Biopharmaceuticals	Pre-clinical	18
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD	Tyra Biosciences	Phase 2	47
rhuFlt3L/CDX-301 + Poly-ICLC	Celldex Therapeutics	Phase 1/2	36
combined therapy with rh-ES and CV	Brain Biotech	Phase 2	44

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved

Dimethyl fumarateApproved

[18F]Florbetapir PET imagingApproved

dimethyl fumarateApproved

ibritumomab tiuxetan (Zevalin®)Approved